Targeted therapy with HER2 and EGFRvIII has improved survival in preclinical models and is expected to breach the blood‒brain barrier, whereas IL-13Rα2 and MSLN have been shown to be potential targets for tumor clearance in brain tumors such as glioblastoma (GBM). This evidence concerns the gene MSLN and glioblastoma.